SillaJen Inc
SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more
SillaJen Inc (215600) - Net Assets
Latest net assets as of September 2025: ₩117.80 Billion KRW
Based on the latest financial reports, SillaJen Inc (215600) has net assets worth ₩117.80 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩124.38 Billion) and total liabilities (₩6.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩117.80 Billion |
| % of Total Assets | 94.71% |
| Annual Growth Rate | 4.73% |
| 5-Year Change | 476.13% |
| 10-Year Change | N/A |
| Growth Volatility | 139.33 |
SillaJen Inc - Net Assets Trend (2015–2024)
This chart illustrates how SillaJen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SillaJen Inc (2015–2024)
The table below shows the annual net assets of SillaJen Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩131.82 Billion | +129.99% |
| 2023-12-31 | ₩57.31 Billion | -27.40% |
| 2022-12-31 | ₩78.94 Billion | -26.94% |
| 2021-12-31 | ₩108.05 Billion | +372.24% |
| 2020-12-31 | ₩22.88 Billion | -86.14% |
| 2018-12-31 | ₩165.09 Billion | -18.25% |
| 2017-12-31 | ₩201.95 Billion | -2.90% |
| 2016-12-31 | ₩207.97 Billion | +139.23% |
| 2015-12-31 | ₩86.94 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SillaJen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43371379180000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩68.68 Billion | 52.11% |
| Other Components | ₩531.32 Billion | 403.08% |
| Total Equity | ₩131.82 Billion | 100.00% |
SillaJen Inc Competitors by Market Cap
The table below lists competitors of SillaJen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
M. Dias Branco S.A. Indústria e Comércio de Alimentos
SA:MDIA3
|
$280.95 Million |
|
Scimee Sci &Tech Co Ltd
SHE:300425
|
$280.96 Million |
|
Beijing ConST Instruments Technology Inc
SHE:300445
|
$281.06 Million |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
$281.14 Million |
|
Anhui Gourgen Traffic Construction Co Ltd
SHG:603815
|
$280.74 Million |
|
HALSTEAD JAMES LS-05
F:HSJA
|
$280.68 Million |
|
Fujian SuperTech Advanced Material Co Ltd
SHG:688398
|
$280.55 Million |
|
Eventbrite Inc Class A
NYSE:EB
|
$280.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SillaJen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,313,962,950 to 131,817,269,900, a change of 74,503,306,950 (130.0%).
- Net loss of 26,525,745,520 reduced equity.
- Share repurchases of 103,155,000,000 reduced equity.
- New share issuances of 103,155,000,000 increased equity.
- Other factors increased equity by 101,029,052,470.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-26.53 Billion | -20.12% |
| Share Repurchases | ₩103.16 Billion | -78.26% |
| Share Issuances | ₩103.16 Billion | +78.26% |
| Other Changes | ₩101.03 Billion | +76.64% |
| Total Change | ₩- | 129.99% |
Book Value vs Market Value Analysis
This analysis compares SillaJen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.59x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.77x to 3.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | ₩319.81 | ₩3445.00 | x |
| 2021-12-31 | ₩1051.13 | ₩3445.00 | x |
| 2022-12-31 | ₩767.95 | ₩3445.00 | x |
| 2023-12-31 | ₩557.57 | ₩3445.00 | x |
| 2024-12-31 | ₩960.12 | ₩3445.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SillaJen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -675.53%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.13x
- Recent ROE (-20.12%) is above the historical average (-52.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -64.25% | -3086.09% | 0.01x | 1.76x | ₩-64.55 Billion |
| 2016 | -35.60% | -1398.97% | 0.02x | 1.37x | ₩-94.84 Billion |
| 2017 | -28.24% | -830.62% | 0.03x | 1.16x | ₩-77.22 Billion |
| 2018 | -34.06% | -729.20% | 0.04x | 1.17x | ₩-72.74 Billion |
| 2020 | -209.03% | -2864.25% | 0.04x | 2.07x | ₩-50.11 Billion |
| 2021 | -14.17% | -6017.12% | 0.00x | 1.25x | ₩-26.11 Billion |
| 2022 | -32.00% | -503.80% | 0.05x | 1.31x | ₩-33.15 Billion |
| 2023 | -35.54% | -517.04% | 0.05x | 1.34x | ₩-26.10 Billion |
| 2024 | -20.12% | -675.53% | 0.03x | 1.13x | ₩-39.71 Billion |
Industry Comparison
This section compares SillaJen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SillaJen Inc (215600) | ₩117.80 Billion | -64.25% | 0.06x | $280.81 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |